美多芭联合普拉克索对帕金森病患者临床症状和血清miR-124、miR-137水平的影响

Effect of madopa combined with pramipexole on clinical symptoms and levels of serum miR-124 and miR-137 in patients with Parkinson disease

目的探讨美多芭联合普拉克索对帕金森病患者临床症状和血清微小核糖核酸-124(miR-124)、微小核糖核酸-137(miR-137)水平的影响。方法抽取2017年7月至2020年8月南阳南石医院收治的帕金森病患者92例,按照治疗方案分为联合组与单一组,每组46例。单一组采用美多芭治疗,联合组采用美多芭联合普拉克索治疗。比较两组疗效,统一帕金森氏病等级量表(UPDRS)评分、非运动症状量表(NMSS)评分,血清miR-124、miR-137水平和不良反应。结果联合组总有效率(93.48%,43/46)高于单一组(78.26%,36/46),差异有统计学意义(P<0.05)。治疗后,联合组UPDRSⅠ、UPDRSⅡ、NMSS评分均低于单一组(P均<0.05)。治疗后,联合组血清miR-124水平高于单一组、血清miR-137水平低于单一组(P<0.05)。联合组不良反应发生率(13.04%,6/46)与单一组(10.87%,5/46)比较差异未见统计学意义(P>0.05)。结论美多芭联合普拉克索治疗帕金森病,可改善患者临床症状,调节血清miR-124、miR-137水平,具备用药安全性。

Objective To investigate the effect of madopar combined with pramipexole on clinical symptoms and serum levels of microRNA-124(miR-124)and microRNA-137(miR-137)in patients with Parkinson disease.Methods A total of 92 patients with Parkinson disease who were admitted to Nanyang Nanshi Hospital from July 2017 to August 2020 were selected,and they were divided into combined group and single group according to the treatment plans,with 46 cases in each group.The single group was treated with madopar,and the combined group was treated with madopar combined with pramipexole.The curative effect,unified Parkinson disease rating scale(UPDRS)score,non-motor symptom scale(NMSS)score,serum miR-124 and miR-137 levels and adverse reactions were compared between the two groups.Results The total effective rate of combined group was 93.48%(43/46),which was higher than 78.26%(36/46)of single group(P<0.05).After treatment,the UPDRSⅠ,UPDRSⅡand NMSS scores in combined group were lower than those in single group(all P<0.05).After treatment,the serum miR-124 level in combined group was higher than that in single group,and the serum miR-137 level was lower than that in single group(P<0.05).The incidence of adverse reactions was 13.04%(6/46)in combined group and 10.87%(5/46)in single group,and there was no significant difference between the two groups(P>0.05).Conclusions Medopa combined with pramipexole in the treatment of Parkinson disease can improve the clinical symptoms of patients,regulate the levels of serum miR-124 and miR-137,and it is safe.